Great Point Partners
The principals of Great Point Partners have a long history of helping executives build successful health care companies.
Business Model:
Revenue: $6.2M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Great Point Partners Information
Geographic Data
Address: 165 Mason Street 3rd Floor
City: Greenwich
State: CT
Zip: 06830
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$422M
Social
Twitter
Linkedin
Crunchbase
Metrics
3,873,674Website Global Rank
3,209Website Monthly Traffic
Twitter Followers
Description
The principals of Great Point Partners have a long history of helping executives build successful health care companies. Their investment team is augmented by their CEO Advisory Board and Medical Advisory Board, members of whom are available to provide advice and assistance to their entrepreneurs and their portfolio companies.
Contact Phone:
+12039713300
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2011 | Cytovance Biologics | Venture Round | 22.5M |
| 7/2022 | Ephicacy | Private Equity Round | - |
| 5/2022 | JPA Health | Private Equity Round | - |
| 9/2021 | BioAtla | Post-IPO Equity | 0 |
| 11/2007 | SGX Pharmaceuticals | Post-IPO Equity | 25M |
| 5/2018 | Clinical Supplies Management | Debt Financing | - |
| 9/2021 | Velentium | Venture Round | - |
| 6/2019 | Bionova Scientific | Private Equity Round | - |
| 1/2004 | Forbes Medi-Tech | Series A | 10.8M |
| 9/2008 | APT Pharmaceuticals | Series B | 32M |
| 2/2014 | Aurinia Pharmaceuticals | Post-IPO Equity | 52M |
| 5/2021 | Magenta Therapeutics | Post-IPO Equity | 86.4M |
| 8/2012 | Connecture | Venture Round | 20M |
| 2/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
| 9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
| 10/2009 | Threshold Pharmaceuticals | Post-IPO Equity | 35M |
| 2/2023 | Abivax | Post-IPO Equity | 0 |
| 10/2018 | Nebula Genomics | Series A | 0 |
| 5/2019 | Axiom Real-Time Metrics | Private Equity Round | - |
| 5/2011 | Biodel | Post-IPO Equity | 30M |
| 3/2010 | BioSante Pharmaceuticals | Post-IPO Equity | 18M |
| 11/2013 | Ocera Therapeutics | Post-IPO Equity | 0 |
| 11/2011 | Aris Radiology | Private Equity Round | - |
| 11/2013 | Health Revenue Assurance Holdings | Venture Round | 5.4M |
| 10/2007 | APT Pharmaceuticals | Series A | 22M |
| 10/2022 | Immunic Therapeutics | Post-IPO Equity | 60M |
| 3/2010 | Solta Medical | Post-IPO Equity | 4.8M |
| 1/2010 | Solta Medical | Post-IPO Equity | 17.2M |
| 12/2004 | Panacos Pharmaceuticals | Post-IPO Equity | 20M |
| 5/2011 | WaferGen Biosystems | Post-IPO Equity | 0 |
| 12/2013 | Bovie Medical | Post-IPO Equity | 7M |
| 6/2013 | iVantage Health Analytics | Private Equity Round | 10M |
| 9/2022 | iXCells Biotechnologies | Private Equity Round | - |
| 8/2022 | Heron Therapeutics | Post-IPO Equity | 76.5M |
| 8/2008 | Biotronic NeuroNetwork | Private Equity Round | - |
| 7/2022 | Ephicacy | Private Equity Round | - |
| 5/2022 | JPA Health | Private Equity Round | - |
| 9/2021 | Velentium | Venture Round | - |
| 9/2021 | BioAtla | Post-IPO Equity | 0 |
| 5/2021 | Magenta Therapeutics | Post-IPO Equity | 0 |
| 2/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
| 6/2019 | Bionova Scientific | Private Equity Round | - |
| 5/2019 | Axiom Real-Time Metrics | Private Equity Round | - |
| 10/2018 | Nebula Genomics | Series A | 0 |
| 5/2018 | Clinical Supplies Management | Debt Financing | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
